PhillyVoice recently ran a profile on 3D bioprinting company BioBots. BioBots began as a bioprinter in computational biology major Danny Cabrera’s Penn State dorm room. Cabrera collaborated with friend and Penn State research specialist Ricky Solorzano.
As Cabrera explains, “I was a senior in college, and this bioprinter ended up being my senior design project. [Cabrera and Solorzano developed the bioprinter prototype] and from there, we started to build a couple of these devices in our dorm room and sold them to scientists around the world.”
This is how BioBots began.
Back in 2015, Cabrera, Solorzano, and third co-founder Sohaib Hashmi “took the top prize at Pennvention…an invention competition with a $5,000 prize and a review from accelerator program DreamIt Ventures.”
Later that same year, BioBots would be accepted into DreamIt’s “second class of startups for its health-focused accelerator, DreamIt Health. The company received $50,000 in funding and office space at the University City Science Center.”
With this funding and real estate, BioBots was able to release the BioBot 1 that year. The BioBot 1 was “the world’s first commercially available desktop 3D bioprinter, with a price tag of $10,000. The BioBot 1 was a sleek, stylish 12-inch cube printing biological tissue with 100-micron resolution.”
Earlier this year, BioBots has released the BioBot 2, with a price tag of $40,000. The BioBot 2 “boasts six temperature-controlled extruders for different biomaterials, sub-micron precision and auto-calibration.”
Over the last several years, BioBots has become quite successful. In fact, “researchers around the world have used BioBots’ printers to make heart, lung, and stomach tissue, along with cartilage and bone.”
Truly, the age of the bioprinter has arrived.
Image and Quotes Courtesy of PhillyVoice